T · 4553.T · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Towa Pharmaceutical Co., Ltd.

$3,345.00as of 2026-11-13 · Mkt cap 188.54B

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Unlock with Pro

Healthcare · Drug Manufacturers - Specialty & Generic Osaka 571-8580 towayakuhin.co.jp

How the business is doing

Fiscal 2012–2026, USD

Revenue
$273.7B+12.1% 5y CAGRd
20122026
Net income
$5.25B-17.8% 5y CAGRd
20122026
Free cash flow
$8.15B+23.2% 5y CAGRd
20122026
Total equity
$178.1B+8.8% 5y CAGRd
20122026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Towa Pharmaceutical Co., Ltd.

        Towa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. The company provides its products in the therapeutic areas of diabetes, digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products. It had a portfolio of approximately 700 drug products. Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.

        CEO
        Itsuro Yoshida
        Employees
        4.59K
        Beta
        -0.10

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.